{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:11:43Z","timestamp":1792059103294,"version":"4.4.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolism"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.diabet.2018.08.010","type":"journal-article","created":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T02:51:25Z","timestamp":1536893485000},"page":"268-275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Effect of liraglutide on physical performance in type 2 diabetes: Results of a randomized, double-blind, controlled trial (LIPER2)"],"prefix":"10.1016","volume":"45","author":[{"given":"A.M.","family":"W\u00e4gner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Miranda-Calder\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Ugarte-Lopetegui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Marrero-Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Su\u00e1rez-Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"L\u00f3pez-Madrazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.","family":"Alberiche-Ruano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Abselam Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Alem\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Castellot-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"D\u00edez del Pino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.J.","family":"N\u00f3voa-Mogoll\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2018.08.010_bib0005","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/dom.12591","article-title":"Incretin therapies: high-lighting common features and differences in the modes of action of glucagon-like peptide-1 agonists and dipeptidyl peptidase-4 inhibitors","volume":"18","author":"Nauck","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2018.08.010_bib0010","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/s12325-014-0164-2","article-title":"Liraglutide for the treatment of diabetes mellitus: a meta-analysis of randomized placebo-controlled trials","volume":"31","author":"Du","year":"2014","journal-title":"Adv Ther"},{"key":"10.1016\/j.diabet.2018.08.010_bib0015","series-title":"Panvascular medicine","article-title":"Gut hormones and the vascular system","author":"W\u00e4gner","year":"2014"},{"key":"10.1016\/j.diabet.2018.08.010_bib0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2337\/dc16-1580","article-title":"Effects of liraglutide on heart rate and heart rate variability: a randomized, double-blind, placebo-controlled, crossover study","volume":"40","author":"Kumarathurai","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.08.010_bib0025","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.08.010_bib0030","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.08.010_bib0035","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.08.010_bib0040","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2018.08.010_bib0045","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/01.CIR.0000120505.91348.58","article-title":"Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion","volume":"109","author":"Nikolaidis","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2018.08.010_bib0050","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.amjcard.2007.05.022","article-title":"Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting","volume":"100","author":"Sokos","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.diabet.2018.08.010_bib0055","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.08.010_bib0060","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/CIRCINTERVENTIONS.110.960476","article-title":"A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans","volume":"4","author":"Read","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.diabet.2018.08.010_bib0065","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/hrt.2010.219345","article-title":"Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease","volume":"98","author":"Read","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.diabet.2018.08.010_bib0070","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/eurheartj\/ehr309","article-title":"Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction","volume":"33","author":"L\u00f8nborg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2018.08.010_bib0075","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.conctc.2016.06.007","article-title":"Effect of liraglutide on physical performance in type 2 diabetes (LIPER2): a randomised, double-blind, controlled trial","volume":"4","author":"W\u00e4gner","year":"2016","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.diabet.2018.08.010_bib0080","doi-asserted-by":"crossref","first-page":"e694","DOI":"10.1161\/CIR.0000000000000406","article-title":"2016 Focused Update: Clinical Recommendations for Cardiopulmonary Exercise Testing Data Assessment in Specific Patient Populations","volume":"133","author":"Guazzi","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2018.08.010_bib0085","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.diabres.2006.07.011","article-title":"Hemodynamic and oxidative stress profile after exercise in type 2 diabetes","volume":"75","author":"Villa-Caballero","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabet.2018.08.010_bib0090","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.euje.2005.12.014","volume":"7","author":"Lang","year":"2006","journal-title":"Euro J Echocardiogr"},{"key":"10.1016\/j.diabet.2018.08.010_bib0095","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1262-3636(17)30068-X","article-title":"GLP-1 receptor agonists and heart failure in diabetes","volume":"43","author":"Scheen","year":"2017","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2018.08.010_bib0100","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMra1510064","article-title":"The primary outcome fails-what next?","volume":"375","author":"Pocock","year":"2016","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.diabet.2018.08.010_bib0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10554-008-9414-1","article-title":"Strain imaging in echocardiography: methods and clinical applications","volume":"25","author":"Nesbitt","year":"2009","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.diabet.2018.08.010_bib0110","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12933-016-0421-6","article-title":"Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study)","volume":"15","author":"Htike","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabet.2018.08.010_bib0115","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)\u2009\u2013\u2009a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.diabet.2018.08.010_bib0120","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2018.08.010_bib0125","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/dom.12900","article-title":"Effect of exercise combined with glucagon-like peptide-1 receptor agonist treatment on cardiac function: a randomized double-blind placebo-controlled clinical trial","volume":"19","author":"J\u00f8rgensen","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2018.08.010_bib0130","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s12020-016-1166-4","article-title":"Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure","volume":"57","author":"Arturi","year":"2017","journal-title":"Endocrine"}],"container-title":["Diabetes & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363618301691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363618301691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:55:54Z","timestamp":1761130554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363618301691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1262363618301691"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2018.08.010","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of liraglutide on physical performance in type 2 diabetes: Results of a randomized, double-blind, controlled trial (LIPER2)","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2018.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}